Litcius/Paper detail

Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial

Gail Brenda Cross, Intan P Sari, Cissy Kityo, Qingshu Lu, Yogesh Pokharkar, Rajesh Babu Moorakonda, Han-Nguyen Thi, Do Quyet, Victoria B. Dalay, Emmanuel Gutierrez, Vincent M. Balanag, Randy Castillo, Henry Mugerwa, Felic Fanusi, Philip Kwan, Ka Lip Chew, Nicholas I. Paton, Cissy Kityo, Henry Mugerwa, D. Tumukunde, Joseph Akol, Do Quyet, Han Nguyen, Xuân Sử Hoàng, Thu Ha Doan, Victoria B. Dalay, Emmanuel Gutierrez, Vincent M. Balanag, Randy Castillo, Monica Barcelo, Rholine Gem Martin S. Veto, Maria Begonia R. Baliwagan, Glenn Balane, Anthony Geronimo, Rupert Rey Flores, Yogesh Pokharkar, Rajesh Babu Moorakonda, Qingshu Lu, Xuanhui Ng, Shanice Tan, Nicholas I. Paton, Gail Brenda Cross, Intan P Sari, Ka Lip Chew, Felic Fanusi, Philip Kwan, Anthony D. Kelleher, Christina C. Chang, Anthony D. Kelleher, Christina C. Chang

2023The Lancet Infectious Diseases28 citationsDOI

Topics & Concepts

MedicineTuberculosisRifampicinEthambutolRosuvastatinSputumInternal medicinePyrazinamideIsoniazidSputum cultureIntention-to-treat analysisRandomized controlled trialSurgeryPathologyTuberculosis Research and EpidemiologyCancer, Lipids, and MetabolismDiagnosis and treatment of tuberculosis